Former Chief Executive Officer and Member of the Board for Affymax, Inc.
Ms. Morris is the President and CEO of Syndax a Boston based epigenetic company. The company is developing entinostat for estrogen receptor positive metastatic breast cancer. The compound is in a Phase 3 NCI sponsored study in combination with exemestane to reverse resistance to hormone therapy in patients Previously she was the chief executive officer and member of the board of directors for Affymax, Inc., a biopharmaceutical company located in Palo Alto, Calif., which was spun out of GlaxoSmithKline (GSK) in 2001 to develop a pipeline of synthetic peptide-based drug candidates for the treatment of anemia in dialysis patients. During her eight years as president and CEO at Affymax, Ms. Morris led the company through the development of OMONTYS peginesatide, a strategic collaboration with Takeda and an Initial Public Offering and several follow on offerings.
Prior to Affymax, Ms. Morris was the president and CEO of Clearview Projects, an advisory firm which counsels biopharmaceutical and biotechnology companies on strategic transactions. Before that she was the senior vice president of business development at Coulter, a biotech company focused on immunotherapeutic approaches to cancer, autoimmune and infectious diseases, where she completed numerous transactions including a $1.0 billion merger between Corixa and Coulter. Ms. Morris began her career at Johnson & Johnson (J&J) as a sales representative rising to vice president of business development.
In addition to Syndax, Ms. Morris serves on the board of directors of Neovacs SA, BIO and Syndax Pharmaceuticals. She was recently on the Humane Society of Silicon Valley and BIO. She received her bachelor’s degree in biology and chemistry from Carlow College.